Published in Sci Rep on April 14, 2016
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer. Am J Cancer Res (2016) 0.75
Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore) (2016) 0.75
Colorectal cancer in cases of multiple primary cancers: Clinical features of 59 cases and point mutation analyses. Oncol Lett (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
A new initiative on precision medicine. N Engl J Med (2015) 16.03
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Annual report on status of cancer in China, 2011. Chin J Cancer Res (2015) 4.62
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 4.54
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer (2007) 1.79
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene (2008) 1.46
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res (2009) 1.35
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 1.12
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One (2013) 0.99
Health: Make precision medicine work for cancer care. Nature (2015) 0.97
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol (2014) 0.96
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer (2013) 0.95
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer (2015) 0.94
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis (2015) 0.79
Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. J Gastrointest Oncol (2015) 0.78